MIAMI BEACH, Florida, Feb. 09 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a new biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the appointment of Dr. Daniel Weinberger on its Scientific Advisory Board (“SAB”).

Dr. Weinberger is Director and CEO of the Lieber Institute for Brain Development at Johns Hopkins Medical Center and Professor of Psychiatry, Neurology, Neuroscience and Human Genetics at Johns Hopkins School of Medicine. He was previously Director of the Genes, Cognition, and Psychosis Program of the Intramural Research Program, National Institute of Mental Health, National Institutes of Health in Bethesda, Maryland. Dr. Weinberger attended college at Johns Hopkins University and the University of Pennsylvania Medical School and did residencies in psychiatry at Harvard Medical School and neurology at George Washington University. He is certified in psychiatry and neurology.

“We are proud to welcome Dr. Daniel Weinberger to our Scientific Advisory Board,” said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics. “For a generation, Dr. Weinberger has been at the forefront of scientific research into neuropsychiatric disorders. His landmark research into the biological origins and genetic expressions of schizophrenia has helped transform the public’s understanding of mental illness. Dr. Weinberger’s expertise and insight will be critical to Pasithea as we advance our mission of developing drugs that target the pathophysiology underlying psychiatric and neurological disorders.

“No treatment used in psychiatry today has been discovered based on an understanding of the causal mechanisms of disease. Pasithea is committed to changing that, to finding new approaches based on fundamental genetic and molecular mechanisms This is music to my ears, and I am thrilled to be part of the advisory team that will help guide this pioneering effort to change the landscape of treatment for neuropsychiatric disorders,” said Dr. Weinberger.

In 2003, Science The magazine highlighted genetic research from Dr. Weinberger’s lab as the second biggest scientific breakthrough of the year, behind the origin of the cosmos. His recent work has focused on the genetic and epigenetic regulation of the expression in the human brain of genes associated with brain developmental disorders.

Dr. Weinberger has published more than 800 articles in peer-reviewed journals and has received numerous honors and awards, including the Sarnat International Prize from the National Academy of Medicine, the Gertrud Reemtsma Foundation International Neuroscience Prize from the Max Planck society. , the NIH Directors Award, the Roche-Nature Medicine Neuroscience Award, the William K. Warren Medical Research Institute Award, the American Psychiatric Association’s Adolf Meyer Prize, the American Psychiatric Association’s Foundation’s Fund Prize, and the Lieber Prize of the Brain and Behavior Research Foundation. He is past president of the Society of Biological Psychiatry and the American College of Neuropsychopharmacology, and was elected to the National Academy of Medicine of the National Academy of Sciences.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is an American biotechnology company focused on the research and discovery of new effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea develops new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on meeting the needs of patients currently suffering from mental illness by providing access to IV ketamine infusions in clinics and at home.

Forward-looking statements

This press release contains statements that constitute “forward-looking statements”. Forward-looking statements are subject to numerous conditions, many of which are beyond the Company’s control. Although the Company believes that these forward-looking statements are reasonable, undue reliance should not be placed on these forward-looking statements, which are based on information available to the Company as of the date of this release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Therefore, actual results could differ materially. The Company undertakes no obligation to update these statements, whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Corp. Contact

Dr Tiago Reis Marques
Chief executive officer
E: [email protected]

Pasithea Therapeutics Corp. Investor Relations

Lisa M. Wilson
Onsite Communications, Inc.
Phone. : 212-452-2793
Email: [email protected]